PERTH, Australia – Australia’s Medical Research Future Fund is pumping AU$40 million (US$29 million) into a national biotech incubator program called CUREator to fund early stage novel therapeutics and preclinical medical research.
HONG KONG – Last week was a busy one for Harbour Biomed Therapeutics Ltd., seeing the company sign a COVID-19 research collaboration with several Dutch institutions as well as lodge an application to list on the Hong Kong Stock Exchange.
HONG KONG- Boehringer Ingelheim International GmbH and Roche Holding AG have announced new initiatives to seek R&D collaborations in China, increasing both their footprint in China and China’s global biopharma presence. Boehringer Ingelheim announced earlier this month the launch of an External Innovation Hub in Shanghai. Meanwhile, Roche China also launched a collaboration initiative this week to develop therapies for gastrointestinal cancer.
BEIJING – Suzhou, China-based Innovent Biologics Inc. is known in China as one of the first drugmakers to launch a PD-1 monoclonal antibody. Now, the company is moving to expand its product portfolio and enhance efforts in developing bispecific antibodies and cell therapies in a potential multibillion-dollar deal with pharma giant Roche Holding AG.
SUZHOU, China – Genome editing startup Edigene Inc. and CAR T developer Immunochina Pharmaceuticals Co. Ltd., both from Beijing, have unveiled joint efforts to develop an allogeneic CAR T therapy for cancer. Terms remain undisclosed.
LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world.